
Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Independent experiment to reproduce HPD/HP phenotype in the humanized TALL-104 HCT-116 p53–/– model. Tumor growth curve of selected humanized control and pembrolizumab treatment group conditions show the HPD/HP phenotype. For each group; n = 4, significance (P < 0.05).